Business Wire

QUIT-LIKE-SWEDEN

10.4.2024 18:33:34 CEST | Business Wire | Press release

Share
Global Drive to ‘Quit Like Sweden’ Will Save Millions of Smokers’ Lives

INTERNATIONAL health experts today rallied behind a major new global effort to replicate Sweden’s success at eradicating smoking by embracing a comprehensive approach that could prevent many millions of premature deaths worldwide.

Quit Like Sweden (QLS), launched at a conference in Brasilia featuring medical professionals, politicians and policymakers, will motivate and support countries worldwide to emulate the triumph of Sweden, which is set to become the first nation to attain official ‘smoke-free’ status later this year.1

QLS founder Suely Castro, a Brazil-born harm reduction advocate, said: “Sweden has achieved this remarkable feat by ensuring that safer alternatives to smoking are accessible, acceptable and affordable.2

“A country where 49% of men used to smoke regularly has virtually wiped out this scourge by allowing its smokers to switch to products that pose just a fraction of the risks, such as snus [traditional smokeless tobacco] and other smoke-free alternatives like vapes and nicotine pouches.3

“Swedes are reaping the health dividend with significantly lower cancer cases and mortality rates compared to their European counterparts4. Now Quit Like Sweden will amplify this message globally, leveraging expertise and fostering collaboration across stakeholders to help countries replicate the Swedish Experience.”

Ms Castro was joined at the launch of her new platform by leading international harm reduction experts who unveiled new research showing that Brazil could save 1.36 million lives by 2060 by adopting the Swedish approach.5

Earlier research has shown that three million more Europeans would be alive today if other countries had implemented Sweden’s comprehensive approach to helping smokers quit.

Meanwhile, a study of low and middle-income countries (LMICs) shows that, through the adoption of Swedish-style policies, Kazakhstan could prevent 165 000 premature deaths in the next four decades, while South Africa, Bangladesh and Pakistan could save 320 000, 920 000, and 1 200 000 lives, respectively.6

Research co-author Dr Anders Milton, a former chair of the World Medical Association and former Secretary General of the Swedish Medical Association, said: “Sweden is winning the war against smoking with a comprehensive approach to tobacco control that supplements traditional cessation and preventive measures with an all-important added element: giving smokers the opportunity to switch to safer alternatives.

“It has set out a policy roadmap that should be treated as a gift to global public health and, potentially, one of the greatest ever breakthroughs in tackling non-communicable diseases (NCDs).

”That’s why QLS is so important. By spreading the message of the Swedish Experience to all corners, many millions of premature deaths - including almost 1.4 million here in Brazil - could be prevented in the next four decades.”

London-based Ms Castro said she had been motivated to launch QLS by her father, a lifelong smoker who lives in Bahia.

“Like Brazil’s other 22 million smokers, my father has been deprived of the lifelines given to the Swedes because of regulatory barriers and societal resistance towards alternative nicotine products.

“Quit Like Sweden aims to empower individuals - here in Brazil, and around the globe - to reclaim control over their health.”

-ENDS-

Notes to editors:

Quit Like Sweden is a platform for people who want to eradicate smoking. The smoking rate in Sweden, where once 49% of the male population smoked regularly, is about to fall below 5%, the level regarded by the World Health Organization as officially ‘smoke-free’. Quit Like Sweden aims to encourage other countries to replicate the Swedish Experience by using traditional cessation and prevention measures while making alternatives to smoking accessible, acceptable and affordable.

An official launch of Quit Like Sweden in Brasilia on April 10 features eminent guest speakers on a variety of topics:

Public policy: Swedish MP Jesper Skalberg Karlsson, Brazilian Senator Soraya Thronicke and Federico Fernandez, We Are Innovation.

Misinformation and the impact on consumers: Miguel Okumura, THR Brasil and Alexandro Lucian, DIRETA.

The Swedish Experience’s life-saving potential for Brazil: Dr Delon Human, Dr Anders Milton and Prof. Dr. Erika Magalhaes Suzigan.

Public health policymaking: Dr Roberto Sussman, Dr Konstantinos Farsalinos, Dr Christopher Russell, David Sweanor, Dr Marewa Glover, Jorge A. Costa e Silva.

1 https://smokefreesweden.org/wp-content/themes/smokefreesweden/assets/pdf/reports/Report%20The%20Swedish%20Experience%20EN.pdf
2 https://www.rcplondon.ac.uk/file/3563/download
3 https://www.ucl.ac.uk/news/2019/oct/e-cigarettes-may-help-over-50000-smokers-quit-england-each-year
4 https://www.researchgate.net/publication/345643346_Tobacco-related_mortality_SwedenEU_easier_readable_charts
5 per co-authored by Dr Delon Human, Dr Anders Milton & Dr Erica Suzigan, 2024.
6 https://smokefreesweden.org/lives-saved.pdf

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410373868/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release

Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour

Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release

Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s

IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release

Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t

Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 22:06:00 CEST | Press release

Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in

Sentinel Midstream Advances Texas GulfLink Deepwater Port5.5.2026 22:00:00 CEST | Press release

Marks Historic Milestone for U.S. Energy Export Infrastructure under the U.S.-Japan Trade Deal Sentinel Midstream LLC (Sentinel) today announced the commencement of its Texas GulfLink deepwater port (Texas GulfLink or the Project), marking a significant milestone enabled by funding received pursuant to the U.S.—Japan Trade Agreement. The project advances in coordination with the U.S. Department of Commerce and the Government of Japan and reflects the shared commitment to strengthening global energy security and expanding U.S. export infrastructure. Sentinel will lead the development of Texas GulfLink, overseeing construction, commercial operations, and long-term management of the terminal. Funding provided under the U.S.—Japan Trade Agreement, pursuant to Executive Order 14345 signed on September 4, 2025, underscores continued international confidence in U.S. energy infrastructure and supports the expansion of American crude oil exports to global markets. Upon this commencement, Texas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye